Overview

Bismuth-containing Quadruple Therapy for Helicobacter Pylori First-line Treatment of Different Tetracycline Doses

Status:
Not yet recruiting

Trial end date:
2022-10-01

Target enrollment:

Participant gender:

Summary

The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a dose and frequency of tetracycline 500mg tid or qid of bismuth quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.

Phase:

Phase 4

Details

Lead Sponsor:

Shandong University

Collaborators:

PKUcare luzhong hospital
Taierzhuang District People's Hospital
Yuncheng Hospital of Traditional Chinese Medicine
Zhengzhou Central Hospital
Zibo Central Hospital

Treatments:

Amoxicillin
Bismuth
Esomeprazole
Potassium Citrate
Tetracycline